文献速递关节外科

基于美国全关节置换登记数据的全髋关节置换假体组合基准评价

Benchmarking THA Implant Combinations Using Data From a US Total Joint Replacement Registry.
PubMed 文献 · Clin Orthop Relat Res · 2025-12-18

研究将国际关节置换登记学会(ISAR)国际假体基准工作组提出的基准方法应用于美国某医疗系统全关节置换登记,纳入2001至2024年因骨关节炎行初次全髋关节置换(THA)且使用高交联聚乙烯髋臼内衬的155123例。多数假体组合在2年、5年、10年、15年时间点获得基准,少数组合(如M/L Taper/Continuum、Kinectiv/Continuum、VerSys/Continuum)未获早期基准,M/L Taper/Trabecular Metal在10年和15年也未获基准。作者认为术者和医疗系统在选择初次THA假体时应考虑这些结果,未获基准的假体应审查失败模式或开展直接对比研究。

要点

  • 86%(30/35)的THA假体组合获得2年基准,覆盖87%(132195/152799)的THA。
  • 5年时90%(27/30)的组合获得基准;10年时13个组合获得优效基准、5个获得非劣效基准。
  • 15年时8个组合中7个获得优效基准;M/L Taper/Trabecular Metal在10年和15年均未获基准。

核心结论

  • ISAR国际假体基准工作组提出的基准方法可应用于美国登记数据,识别出性能优效或达标以及未达基准的假体组合。
  • 作者认为术者和医疗系统在选择初次THA假体时应考虑这些结果,未获基准的假体应审查失败模式或开展直接对比研究。
  • 作者认为该基准方法应纳入美国登记系统。

研究设计与样本

  • 基于美国某医疗系统全关节置换登记的队列研究,登记为监测工具,通过电子健康记录收集所有THA的假体信息并与条码扫描信息交叉核对。
  • 纳入2001至2024年因骨关节炎行初次THA且使用高交联聚乙烯髋臼内衬者,最终样本为67家医院509名术者完成的155123例初次THA。
  • 患者平均±SD年龄67±10岁,BMI 29±5 kg/m²;女性占57%(89092/155123),白人占79%(121913/155123),美国麻醉医师学会分级1或2级占64%(98913/155123)。
  • 随访至患者退出医疗计划或死亡,2、5、10、15年因会员终止而失访的比例分别为4%、9%、16%、22%;翻修经病历审查人工核实。
  • 采用1减Kaplan-Meier估计计算全因累积翻修百分比(CPR)及95%CI,每个时间点需至少250例THA仍在风险中才考虑基准评价,比较95%CI而非CPR与基准标准。

主要发现

  • 2年时86%(30/35)的THA假体组合获得基准(95%CI下限≤2%翻修率标准),代表87%(132195/152799)的THA。
  • 未获2年基准的5个假体系统为:Zimmer-Biomet M/L Taper®/Continuum®(2年随访仍在风险n=9903,CPR 3.1[95%CI 2.8至3.5])、Zimmer-Biomet Trabecular Metal®/Continuum(n=2939,CPR 3.2[95%CI 2.6至3.8])、Zimmer-Biomet Kinectiv®/Continuum(n=2467,CPR 2.7[95%CI 2.1至3.3])、Zimmer-Biomet M/L Taper/Trabecular Metal®(n=2375,CPR 2.7[95%CI 2.1至3.4])和Zimmer-Biomet VerSys®/Continuum(n=772,CPR 3.3[95%CI 2.3至4.8])。
  • 5年时30个组合中90%(27个)获得基准(95%CI下限≤3%标准),覆盖90%(131904/146465)的THA;M/L Taper/Continuum、Kinectiv/Continuum和VerSys/Continuum均未获2年和5年基准。
  • 10年时20个组合中13个获得优效基准(95%CI上限≤5%标准,覆盖80%[83134/103919]的THA),另5个获得非劣效基准(95%CI上限≤6%,覆盖15%[15528/103919]的THA);M/L Taper/Trabecular Metal和Kinectiv/Continuum未获10年基准,且在此前时间点也未获基准。
  • 15年时8个组合中7个获得优效基准(95%CI上限≤6.5%标准,覆盖97%[74613/77204]的THA);M/L Taper/Trabecular Metal再次未获基准,与更早时间点一致;按性别和年龄分层分析中未获基准的组合与总体分析一致。

关键数值与推荐

  • 早期基准:2年时95%CI下限≤2%翻修率标准、5年时≤3%标准即获得基准。
  • 10年中点基准:标准为5%翻修率,95%CI上限≤5%为优效基准;非劣效界值为高于标准20%的相对翻修率,即95%CI上限≤6%(5%标准上浮20%,即1%非劣效界值)获得非劣效基准,上限>6%则未获基准。
  • 15年晚期基准:标准为6.5%翻修率,95%CI上限≤6.5%为优效基准、≤7.8%为非劣效基准,上限>7.8%未获基准。
  • 每个评价时间点需至少250例THA仍在风险中才考虑基准评价。

临床怎么用

  • 作者认为术者和医疗系统在选择初次THA假体时应考虑这些基准结果。
  • 作者认为未获基准的假体应审查其失败模式或开展直接对比研究。
  • 作者认为该基准方法应纳入美国登记系统。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benchmarking is a surveillance methodology used to evaluate implants against predetermined standards at select time points after surgery. Receiving a benchmark indicates that an implant has acceptable revision-free survivorship based on a predefined set of standards. Assessing implant performance against benchmarks offers valuable insights for surgeons, industry, and regulatory bodies, and also serves as a foundation for future evidence-based research. QUESTIONS/PURPOSES: We sought to apply the benchmarking standards proposed by the International Society of Arthroplasty Registries (ISAR) International Prosthesis Benchmarking Working Group to our US-based healthcare system's total joint replacement registry and determine and identify THA implant constructs, as well as individual femoral stem and acetabular cup components, that received benchmarks at (1) early 2- and 5-year time points, (2) the midpoint 10-year time point, and (3) the late 15-year time point. As a secondary aim, (4) we sought to evaluate the consistency of these benchmarks when stratified by gender and age. METHODS: Data from our US-based healthcare system's total joint replacement registry was used to conduct a cohort study. The registry is a surveillance tool that collects a predefined set of information, including implants used, for all THAs performed within the healthcare system. Surgeons complete interoperative registry forms via the electronic health record (EHR) for all THAs. This information is cross-checked with implant information, including manufacturer, implant, and catalog number, that is recorded into the EHR via barcode scan and then extracted into the registry. Patients are longitudinally followed for outcomes, including revision surgery, after their THA until they either leave the healthcare plan or they die, and identified revisions were manually validated through chart review. Primary THAs with highly crosslinked polyethylene acetabular liners for osteoarthritis were identified (2001 to 2024). The final eligible sample included 155,123 primary THAs performed by 509 surgeons at 67 hospitals. The mean ± SD patient age and BMI were 67 ± 10 years and 29 ± 5 kg/m 2 , respectively. More patients were women (57% [89,092 of 155,123]), White (79% [121,913 of 155,123]), and had an American Society of Anesthesiologists classification of 1 or 2 (64% [98,913 of 155,123]). The proportions of the cohort lost to follow-up through membership termination were 4%, 9%, 16%, and 22% at 2, 5, 10, and 15 years, respectively. The all-cause cumulative percent revision (CPR) and 95% confidence intervals (CIs) during follow-up were calculated using 1 - the Kaplan-Meier estimate. Standards proposed by the International Prosthesis Benchmarking Working Group to identify benchmarks were used; at each time point of interest, there needed to be at least 250 THAs still at risk at that time of follow-up to be considered for benchmarking, and 95% CIs rather than the CPR were compared with the benchmark standard. For early benchmarks, constructs received a benchmark if the lower bound of the 95% CI was less than or equal to the 2% revision rate standard at 2 years and less than or equal to the 3% standard at 5 years. For midpoint benchmarks at 10 years, a 5% revision rate was the benchmark standard, and both superiority and noninferiority relative to the standard was considered. A superior benchmark was received if the upper bound of the 95% CI was ≤ 5%. For noninferiority, the margin was set at a 20% higher relative revision rate than the standard. Therefore, a noninferiority benchmark was received if the upper bound was ≤ 6% (20% above the 5% standard, or a 1% noninferiority margin); if the upper bound was above the noninferiority threshold of 6%, then the implant failed to receive a benchmark. Superiority and noninferiority were also considered for late benchmarks at 15 years with a 6.5% revision rate benchmark standard. A superior benchmark was received if the upper bound was ≤ 6.5%, noninferior if the upper bound was ≤ 7.8%, and no benchmark was received if the upper bound was > 7.8%. RESULTS: Most (86% [30 of 35]) THA constructs that we considered received a 2-year benchmark, meaning that the lower bound of the 95% CI was less than or equal to the benchmark standard of a 2% revision rate, representing 87% (132,195 of 152,799) of the THAs. The five implant systems not receiving a 2-year benchmark were the Zimmer-Biomet M/L Taper®/Continuum® (n = 9903 still at risk at 2-year follow-up, CPR 3.1 [95% CI 2.8 to 3.5]), Zimmer-Biomet Trabecular Metal®/Continuum (n = 2939, CPR 3.2 [95% CI 2.6 to 3.8]), Zimmer-Biomet Kinectiv®/Continuum (n = 2467, CPR 2.7 [95% CI 2.1 to 3.3]), Zimmer-Biomet M/L Taper/Trabecular Metal® (n = 2375, CPR 2.7 [95% CI 2.1 to 3.4]), and Zimmer-Biomet VerSys®/Continuum (n = 772, CPR 3.3 [95% CI 2.3 to 4.8]). Of the 30 constructs for the 5-year time point, 90% (27) received a benchmark, meaning that the lower bound of the 95% CI was less than or equal to the 3% benchmark standard, used in 90% (131,904 of 146,465) of the THAs considered. The M/L Taper/Continuum, Kinectiv/Continuum, and VerSys/Continuum all failed to receive a 2-year and 5-year benchmark. There were 20 constructs evaluated at the 10-year midpoint, and 13 received a superior benchmark with the upper bound less than or equal to the 5% benchmark standard (80% [83,134 of 103,919] of THAs evaluated), while another five constructs received a noninferior benchmark with the upper bound ≤ 6% (15% [15,528 of 103,919] of THAs evaluated). The M/L Taper/Trabecular Metal and Kinectiv/Continuum did not receive a midpoint benchmark; these constructs also failed to receive benchmarks at earlier time points. There were eight constructs evaluated at the 15-year late time point, seven of which received a superior benchmark with the upper bound of the 95% CI less than or equal to the benchmark standard of 6.5% (97% [74,613 of 77,204] of THAs evaluated). The M/L Taper/Trabecular Metal again failed to receive a benchmark, consistent with earlier time points. Constructs failing to receive a benchmark in gender and stratified analyses were consistent with those already identified in the overall analysis. CONCLUSION: The proposed ISAR International Prosthesis Benchmarking Working Group benchmarking methodology was applied to a US-based registry and identified distinct implant combinations as superior or adequate performing, as well as those that failed to meet the benchmarks for having a revision rate within the predefined range. Surgeons and health systems should take these findings into consideration when selecting implants for primary THA. Implants that do not receive benchmarks should be scrutinized for modes of failure or subject to direct comparative studies. The benchmarking methodology should be incorporated into US-based registries. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Sambare TD, Son SJ, Sun H, et al. Benchmarking THA Implant Combinations Using Data From a US Total Joint Replacement Registry. Clin Orthop Relat Res. 2025. PMID: 41460256. doi:10.1097/CORR.0000000000003799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。